Idera Pharmaceuticals, Inc. (IDRA) |
|
0.425 -0.127 (-23.04%)
|
01-17 16:00 |
|
Open: |
0.4768 |
Pre. Close: |
0.5522 |
|
High:
|
0.51 |
Low:
|
0.4201 |
|
Volume:
|
371,878 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:26:59 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 5.51 One year: 6.35 |
| Support: |
Support1: 3.56 Support2: 2.97 |
| Resistance: |
Resistance1: 4.72 Resistance2: 5.44 |
| Pivot: |
4.26 |
| Moving Average: |
MA(5): 4 MA(20): 4.41
MA(100): 5.71 MA(250): 6.94 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 12.3 %D(3): 10.7  |
| RSI: |
RSI(14): 37.2 |
| 52-week: |
High: 16 Low: 0.42 |
| Average Vol(K): |
3-Month: 51 (K) 10-Days: 13 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IDRA ] has closed below the lower bollinger band by 17.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ IDRA ] is to continue within current trading range. It is unclear right now based on current values. 72.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.14 - 4.17 |
4.17 - 4.19 |
|
Low:
|
3.52 - 3.55 |
3.55 - 3.57 |
|
Close:
|
3.54 - 3.57 |
3.57 - 3.61 |
|
Company Description |
|
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania. |
Headline News |
Tue, 17 Jan 2023
Aeterna discontinues vaccine development; Idera rebrands as ... - Endpoints News
Tue, 17 Jan 2023
ACERAGEN, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Tue, 17 Jan 2023
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook - Yahoo Finance
Thu, 29 Sep 2022
Idera Pharma Acquires Rare Disease Player, Names New CEO - Yahoo Finance
Wed, 28 Sep 2022
Idera Pharmaceuticals completes acquisition of Aceragen - Seeking Alpha
Wed, 28 Sep 2022
Idera Pharmaceuticals Acquires Aceragen - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
-0.12 |
|
EPS Est This Year
|
-0.48 |
|
EPS Est Next Year
|
-0.5 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.18 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.37 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2018-07-29 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
